In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Resolve and Takeda work together to develop nuclease proteins for lupus

Executive Summary

Resolve Therapeutics LLC (targeted biologics for lupus) has found its first major pharma partner through a new deal with Takeda Pharmaceutical Co. Ltd. The companies will further develop Resolve’s preclinical lupus candidate RSLV132, with Takeda retaining an exclusive option for global rights to the agent and all other compounds in the start-up’s pipeline.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies